Mario Scartozzi

Research interests

Publications

• Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

  Liver International · 2023 · https://doi.org/10.1111/liv.15641

• EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment

  International Journal of Molecular Sciences · 2022 · https://doi.org/10.3390/ijms23126489

• Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

  ESMO Open · 2022 · https://doi.org/10.1016/j.esmoop.2022.100591

• Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

  European Journal of Cancer · 2022 · https://doi.org/10.1016/j.ejca.2022.11.017

• Immune Checkpoint Inhibitors in the Treatment of HCC

  Frontiers in Oncology · 2021 · https://doi.org/10.3389/fonc.2020.601240

• Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

  World Journal of Gastroenterology · 2018 · https://doi.org/10.3748/wjg.v24.i36.4152

• HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

  International Journal of Cancer · 2016 · https://doi.org/10.1002/ijc.30408

• Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy

  Journal of Cardiovascular Medicine · 2016 · https://doi.org/10.2459/jcm.0000000000000376

• VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study

  International Journal of Cancer · 2014 · https://doi.org/10.1002/ijc.28772

• Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mdr623

• PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.20.2796

• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

  Annals of Oncology · 2008 · https://doi.org/10.1093/annonc/mdn637

• Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

  The Lancet Oncology · 2008 · https://doi.org/10.1016/s1470-2045(07)70383-2

• Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.11.5022

• Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies

  Journal of Clinical Oncology · 2004 · https://doi.org/10.1200/jco.2004.00.117

Current projects

No projects listed.